Seres Therapeutics (NASDAQ:MCRB) Earns “Buy” Rating from Chardan Capital

Seres Therapeutics (NASDAQ:MCRB)‘s stock had its “buy” rating reaffirmed by analysts at Chardan Capital in a research report issued to clients and investors on Wednesday,Benzinga reports. They currently have a $1.25 target price on the biotechnology company’s stock. Chardan Capital’s target price would suggest a potential upside of 111.79% from the stock’s current price.

Several other research analysts have also commented on the company. Canaccord Genuity Group reaffirmed a “buy” rating and set a $10.00 price target on shares of Seres Therapeutics in a research report on Friday, September 13th. StockNews.com cut shares of Seres Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, August 13th. Finally, JPMorgan Chase & Co. lowered shares of Seres Therapeutics from a “neutral” rating to an “underweight” rating in a research note on Thursday, October 24th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat.com, Seres Therapeutics currently has an average rating of “Hold” and a consensus target price of $5.08.

Seres Therapeutics Trading Down 11.1 %

NASDAQ:MCRB traded down $0.07 during trading hours on Wednesday, hitting $0.59. The company’s stock had a trading volume of 5,426,953 shares, compared to its average volume of 4,340,406. Seres Therapeutics has a 52-week low of $0.54 and a 52-week high of $2.05. The stock has a market capitalization of $100.45 million, a P/E ratio of -0.50 and a beta of 2.06. The stock has a fifty day moving average of $0.87 and a 200-day moving average of $0.92.

Seres Therapeutics (NASDAQ:MCRB) last announced its quarterly earnings results on Tuesday, August 13th. The biotechnology company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.30) by $0.08. During the same quarter last year, the business earned $0.36 EPS. On average, sell-side analysts forecast that Seres Therapeutics will post -0.92 earnings per share for the current year.

Institutional Trading of Seres Therapeutics

Several hedge funds have recently modified their holdings of the business. Vanguard Group Inc. boosted its stake in shares of Seres Therapeutics by 12.1% during the 1st quarter. Vanguard Group Inc. now owns 6,734,821 shares of the biotechnology company’s stock worth $5,213,000 after acquiring an additional 729,514 shares in the last quarter. Vontobel Holding Ltd. purchased a new stake in Seres Therapeutics during the third quarter worth $374,000. Charles Schwab Investment Management Inc. increased its position in shares of Seres Therapeutics by 42.4% in the third quarter. Charles Schwab Investment Management Inc. now owns 748,718 shares of the biotechnology company’s stock valued at $708,000 after buying an additional 222,771 shares in the last quarter. FMR LLC boosted its position in shares of Seres Therapeutics by 0.6% in the 3rd quarter. FMR LLC now owns 22,857,260 shares of the biotechnology company’s stock worth $21,625,000 after buying an additional 140,096 shares in the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new stake in Seres Therapeutics in the 2nd quarter valued at about $92,000. 59.34% of the stock is owned by institutional investors and hedge funds.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.